Trial Profile
Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Egyptian Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DAPA-Egypt
- Sponsors AstraZeneca
- 10 Jun 2020 Status changed from active, no longer recruiting to completed.
- 27 Feb 2020 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Dec 2019 Planned End Date changed from 30 Dec 2019 to 31 Mar 2020.